Deep Medicine Acquisition (Deep Medicine Acquisition) Cash-to-Debt : 0.17 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Deep Medicine Acquisition's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.17.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Deep Medicine Acquisition couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Deep Medicine Acquisition's Cash-to-Debt or its related term are showing as below:

DMAQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 1 Max: 1.95
Current: 0.17

During the past 3 years, Deep Medicine Acquisition's highest Cash to Debt Ratio was 1.95. The lowest was 0.17. And the median was 1.00.

DMAQ's Cash-to-Debt is not ranked
in the Diversified Financial Services industry.
Industry Median: 3.34 vs DMAQ: 0.17

Deep Medicine Acquisition Cash-to-Debt Historical Data

The historical data trend for Deep Medicine Acquisition's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Deep Medicine Acquisition Cash-to-Debt Chart

Deep Medicine Acquisition Annual Data

Trend

Mar21

Mar22

Mar23

Cash-to-Debt

1.00

1.75

0.32

Deep Medicine Acquisition Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial							1.03	0.55	0.32	0.26	0.17

Competitive Comparison of Deep Medicine Acquisition's Cash-to-Debt

For the Shell Companies subindustry, Deep Medicine Acquisition's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deep Medicine Acquisition's Cash-to-Debt Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's Cash-to-Debt falls into.

Deep Medicine Acquisition Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Deep Medicine Acquisition's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.596	/	(1.865	+	0)
	=	0.32

Deep Medicine Acquisition's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.357	/	(2.15	+	0)
	=	0.17

Deep Medicine Acquisition (NAS:DMAQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Deep Medicine Acquisition Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Madison Avenue, 12th Floor, New York, NY, USA, 10017

Website

Deep Medicine Acquisition Corp is a blank check company.

Executives

John Chiang	director	3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen	director, officer: Chief Executive Officer	C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo	officer: Chief Financial Officer	40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc	10 percent owner	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017